181 related articles for article (PubMed ID: 15086570)
1. CD158k/KIR3DL2 is a new phenotypic marker of Sezary cells: relevance for the diagnosis and follow-up of Sezary syndrome.
Poszepczynska-Guigné E; Schiavon V; D'Incan M; Echchakir H; Musette P; Ortonne N; Boumsell L; Moretta A; Bensussan A; Bagot M
J Invest Dermatol; 2004 Mar; 122(3):820-3. PubMed ID: 15086570
[TBL] [Abstract][Full Text] [Related]
2. CD158K/KIR3DL2 transcript detection in lesional skin of patients with erythroderma is a tool for the diagnosis of Sézary syndrome.
Ortonne N; Le Gouvello S; Mansour H; Poillet C; Martin N; Delfau-Larue MH; Leroy K; Farcet JP; Bagot M; Bensussan A
J Invest Dermatol; 2008 Feb; 128(2):465-72. PubMed ID: 17703174
[TBL] [Abstract][Full Text] [Related]
3. CD158k/KIR3DL2 is a useful marker for identifying neoplastic T-cells in Sézary syndrome by flow cytometry.
Bahler DW; Hartung L; Hill S; Bowen GM; Vonderheid EC
Cytometry B Clin Cytom; 2008 May; 74(3):156-62. PubMed ID: 18061949
[TBL] [Abstract][Full Text] [Related]
4. CD158k is a reliable marker for diagnosis of Sézary syndrome and reveals an unprecedented heterogeneity of circulating malignant cells.
Moins-Teisserenc H; Daubord M; Clave E; Douay C; Félix J; Marie-Cardine A; Ram-Wolff C; Maki G; Beldjord K; Homyrda L; Michel L; Bensussan A; Toubert A; Bagot M
J Invest Dermatol; 2015 Jan; 135(1):247-257. PubMed ID: 25158034
[TBL] [Abstract][Full Text] [Related]
5. Significance of circulating T-cell clones in Sezary syndrome.
Ortonne N; Huet D; Gaudez C; Marie-Cardine A; Schiavon V; Bagot M; Musette P; Bensussan A
Blood; 2006 May; 107(10):4030-8. PubMed ID: 16418328
[TBL] [Abstract][Full Text] [Related]
6. Membrane expression of NK receptors CD160 and CD158k contributes to delineate a unique CD4+ T-lymphocyte subset in normal and mycosis fungoides skin.
Sako N; Schiavon V; Bounfour T; Dessirier V; Ortonne N; Olive D; Ram-Wolff C; Michel L; Sicard H; Marie-Cardine A; Bagot M; Bensussan A; Schmitt C
Cytometry A; 2014 Oct; 85(10):869-82. PubMed ID: 25044837
[TBL] [Abstract][Full Text] [Related]
7. Absolute CD3+ CD158k+ lymphocyte count is reliable and more sensitive than cytomorphology to evaluate blood tumour burden in Sézary syndrome.
Bouaziz JD; Remtoula N; Bensussan A; Marie-Cardine A; Bagot M
Br J Dermatol; 2010 Jan; 162(1):123-8. PubMed ID: 19681856
[TBL] [Abstract][Full Text] [Related]
8. Engagement of ILT2/CD85j in Sézary syndrome cells inhibits their CD3/TCR signaling.
Nikolova M; Musette P; Bagot M; Boumsell L; Bensussan A
Blood; 2002 Aug; 100(3):1019-25. PubMed ID: 12130517
[TBL] [Abstract][Full Text] [Related]
9. CD158k and PD-1 expressions define heterogeneous subtypes of Sezary syndrome.
Vergnolle I; Douat-Beyries C; Boulinguez S; Rieu JB; Vial JP; Baracou R; Boudot S; Cazeneuve A; Chaugne S; Durand M; Estival S; Lablanche N; Nicolau-Travers ML; Tournier E; Lamant L; Vergez F
Blood Adv; 2022 Mar; 6(6):1813-1825. PubMed ID: 34570200
[TBL] [Abstract][Full Text] [Related]
10. Expression and function of the natural cytotoxicity receptor NKp46 on circulating malignant CD4+ T lymphocytes of Sézary syndrome patients.
Bensussan A; Remtoula N; Sivori S; Bagot M; Moretta A; Marie-Cardine A
J Invest Dermatol; 2011 Apr; 131(4):969-76. PubMed ID: 21191411
[TBL] [Abstract][Full Text] [Related]
11. Polymorphic expression of CD158k/p140/KIR3DL2 in Sézary patients.
Musette P; Michel L; Jean-Louis F; Bagot M; Bensussan A
Blood; 2003 Feb; 101(3):1203. PubMed ID: 12529298
[No Abstract] [Full Text] [Related]
12. The diagnosis of Sézary syndrome on peripheral blood by flow cytometry requires the use of multiple markers.
Klemke CD; Brade J; Weckesser S; Sachse MM; Booken N; Neumaier M; Goerdt S; Nebe TC
Br J Dermatol; 2008 Sep; 159(4):871-80. PubMed ID: 18652582
[TBL] [Abstract][Full Text] [Related]
13. Killer cell immunoglobulin-like receptor expression delineates in situ Sézary syndrome lymphocytes.
Wechsler J; Bagot M; Nikolova M; Parolini S; Martin-Garcia N; Boumsell L; Moretta A; Bensussan A
J Pathol; 2003 Jan; 199(1):77-83. PubMed ID: 12474229
[TBL] [Abstract][Full Text] [Related]
14. SC5 mAb represents a unique tool for the detection of extracellular vimentin as a specific marker of Sezary cells.
Huet D; Bagot M; Loyaux D; Capdevielle J; Conraux L; Ferrara P; Bensussan A; Marie-Cardine A
J Immunol; 2006 Jan; 176(1):652-9. PubMed ID: 16365461
[TBL] [Abstract][Full Text] [Related]
15. [Epidermotropic T cell lymphomas as models for tumor progression].
Bagot M; Bensussan A
Med Sci (Paris); 2006 Feb; 22(2):192-6. PubMed ID: 16457762
[TBL] [Abstract][Full Text] [Related]
16. Use of PLS3, Twist, CD158k/KIR3DL2, and NKp46 gene expression combination for reliable Sézary syndrome diagnosis.
Michel L; Jean-Louis F; Begue E; Bensussan A; Bagot M
Blood; 2013 Feb; 121(8):1477-8. PubMed ID: 23429988
[No Abstract] [Full Text] [Related]
17. CD158k/KIR3DL2 and NKp46 are frequently expressed in transformed mycosis fungoides.
Ortonne N; Le Gouvello S; Tabak R; Marie-Cardine A; Setiao J; Berrehar F; Nghe-Tang A; Martin N; Bagot M; Bensussan A
Exp Dermatol; 2012 Jun; 21(6):461-3. PubMed ID: 22621189
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of KIR3DL2 to Diagnose, Follow-Up, and Manage the Treatment of Patients with Sézary Syndrome.
Hurabielle C; Thonnart N; Ram-Wolff C; Sicard H; Bensussan A; Bagot M; Marie-Cardine A
Clin Cancer Res; 2017 Jul; 23(14):3619-3627. PubMed ID: 28119365
[No Abstract] [Full Text] [Related]
19. CD164 identifies CD4
Benoit BM; Jariwala N; O'Connor G; Oetjen LK; Whelan TM; Werth A; Troxel AB; Sicard H; Zhu L; Miller C; Takeshita J; McVicar DW; Kim BS; Rook AH; Wysocka M
Arch Dermatol Res; 2017 Jan; 309(1):11-19. PubMed ID: 27766406
[TBL] [Abstract][Full Text] [Related]
20. Circulating and skin-derived Sézary cells: clonal but with phenotypic plasticity.
Roelens M; Delord M; Ram-Wolff C; Marie-Cardine A; Alberdi A; Maki G; Homyrda L; Bensussan A; Bagot M; Toubert A; Moins-Teisserenc H
Blood; 2017 Sep; 130(12):1468-1471. PubMed ID: 28760889
[No Abstract] [Full Text] [Related]
[Next] [New Search]
